Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China
Triple therapy with finerenone, SGLT2i, and SoC is cost-effective for Chinese patients with T2D and CKD, delivering synergistic cardiovascular and renal protective effects while demonstrating robust economic viability within China's healthcare framework.
Authors
- Lejun Zhang (ORCID: https://orcid.org/0000-0002-2706-0551)
- Zhengqiang Hu (ORCID: https://orcid.org/0000-0002-7126-9379)
- Wei Jin (ORCID: https://orcid.org/0000-0003-1264-7541)
- Lou S (ORCID: https://orcid.org/0009-0007-9444-6378)
Institutions
- Zhejiang International Studies University (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/0886022x.2025.2578413
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00